Krystal Biotech (KRYS) Stifel 2024 Healthcare Conference summary

Pipeline and clinical development

• Focus on genetic medicines for rare, monogenic diseases using a redosable HSV vector platform.

• Vyjuvek approved for dystrophic epidermolysis bullosa, with European approval expected soon and potential Japanese approval in 2025.

• KB408 (alpha-1 antitrypsin) phase I/II data expected by end of year, with efficacy insights from bronch data in cohort two.

• Decision to advance dosing cohorts will depend on achieving 5–10% lung AAT levels, with re-dosing data likely by end of 2025.

• CF and oncology programs progressing, with CF data expected in first half of 2025 and ongoing efforts to address regulatory and enrollment challenges.

Regulatory and competitive landscape

• No changes to trial protocol due to competition; patient willingness enabled earlier efficacy data collection.

• Regulatory path for alpha-1 antitrypsin hinges on molecular data and agency discussions; accelerated approval could keep the program in-house, while broader trials may prompt partnering.

• CF Foundation's concerns center on preclinical model compatibility; clinical data may help overcome enrollment barriers.

Commercialization and growth strategy

• U.S. Vyjuvek launch progressing, aiming for 720 reimbursement approvals and targeting up to 3,000 patients.

• European launch contingent on CHMP/EMA approval, with a goal of 60% market share two years post-launch in each country.

• Pricing in Europe expected to be about 50% of U.S. levels, with variations by country and no cap structure planned.

• Distribution agreements in MENA, Eastern Europe, and Israel expected to add patients in 2025.